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BACKGROUND: Children younger than 15 years, carry almost 
80% of the global burden of HIV/AIDS. HIV worsens the 
progression of latent TB to active TB disease. Although 
antiretroviral treatment has shown marked reduction in 
Tuberculosis incidence, TB continues to occur in Sub-Saharan 
countries including Ethiopia. The aim of this study was to 
investigate the impact of HAART on the incidence of tuberculosis 
among children infected with HIV in Southwest Ethiopia. 
METHODS: A retrospective cohort study was conducted between 
2009 to 2014. We used chi-square test, and Mann-Whitney U test 
to compare non-HAART and HAART cohort. We estimated the 
effect of HAART on TB incidence using marginal structural 
model after adjusting for time-dependent confounders affected by 
exposure. 
RESULT: A total of 844 children were followed. We observed 
them for a median of 51 months (IQR 31) and a total of 2942.99 
child-years. The overall TB incidence rate was 7.917 per 100 
child years (95% CI, 6.933-9.002). TB incidence for specific 
HAART and non-HAART cohort were 7.67 per 100 child-years 
(95% CI, 6.318-9.217) and 8.17 per 100 child-years (95% CI, 
6.772-9.767) respectively. From marginal structural modeling, 
children on HAART were 36% (HR=0.642, 95% CI 0.442-0.931, 
p<0.02) less likely to develop TB compared to those who were not. 
CONCLUSION: HAART reduced the hazard of TB in HIV-
infected children by 36%. This is by far less than what is 
expected.  





Children younger than 15 years, carry almost 80% of the global 
burden of HIV/AIDS. Infection with HIV is an important risk factor 
for Tuberculosis (1).Worldwide TB is the most common 
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opportunistic illness and the leading cause of 
death among HIV infected children (2,3). A total 
of 1.5 million people died from TB in 2018 
(including 251,000 people with HIV). In the same 
year, 1.1 million children fell ill with TB globally, 
and there were 20% child deaths due to TB 
(including among children with HIV)(4). 
According to WHO, there were an estimated 0.9 
million new cases of TB amongst people who 
were HIV-positive, 72% of whom were living in 
Africa (3). Around 15-20% of TB cases were 
estimated among children in settings with a high 
burden of TB (5,6).  
HIV and TB form a lethal combination, each 
speeding the other's progress (7,8).  People with 
Latent TB have lifetime risk of 10-15% to develop 
active TB disease. The risk of developing TB in 
HIV-infected children is 20 times higher than 
HIV-uninfected children (9). Without 
treatment,15–50% of HIV-positive infants and 
children will develop active TB within two years 
after becoming infected with TB (10).  
To prevent TB, highly active antiretroviral 
therapy(HAART) is one of the strategies 
recommended by the World Health Organization 
(WHO) (11,12). HAART has shown marked 
reduction in the incidence of Tuberculosis (13–
15).  Although the risk of developing TB is 
reduced by 70%–90% among HIV-infected 
persons receiving HAART compared with 
untreated individuals (16), TB risk remains high 
following HAART initiation (17,18). 
Higher risk may be partially due to 
incomplete immune restoration and “unmasking” 
of previously undiagnosed TB in the setting of 
immune reconstitution (19).  The effect of 
HAART on TB incidence in resource constrained 
country  may be   adversely affected by multiple 
factors including delayed presentation to care and 
a higher incidence of co-occurring infectious and 
non-infectious conditions such as under nutrition 
and adherence level (13) . 
  HIV-infected children are most at risk to 
develop tuberculosis. Globally, from  estimated 10 
million new TB infections, 1 million of them  
were children less than  15 years of age in 2017 
(20). In Ethiopia,  reported number of PLHIV 
treated with  HAART were 71%, and out of  this 
32% have suppressed viral load measurement in 
2017 (21). TB case notification for TB was 6% 
with rapid diagnostic tool while TB preventive 
treatment reached 47% (22). Routine screening 
and treatment for latent TB infection (LTBI) has 
been shown to reduce the risk of active TB in 
HIV-infected patients (23). 
In Ethiopia, few studies examined the 
incidence of TB among children on HAART. 
These few  studies have attempted to draw a 
causal inference regarding the effect of HAART 
on TB(6,24,25). However, their analysis was 
biased. The bias comes from using standard 
methods for estimating treatment effect in cohort 
study. Standard method cannot allow us control 
time-varying confounders.  The bias in estimating 
the causal effect of treatment in the presence of 
time-varying confounders could be addressed 
using marginal structural modeling: a method 
based on deriving  inverse-probability-of-
treatment-weights, which is then used in a pooled 
logistic regression model (26). We estimated 
effect of HAART on the incidence of TB among 
HIV infected children using marginal structural 
regression modeling after adjusting and weighting 
baseline and time varying covariates.  
MATERIALS AND METHODS  
 
Study design and setting: A retrospective cohort 
study was conducted for five years from 2009 to 
2014. The study was conducted in selected ART 
clinics found in southwest Ethiopia. Southwest 
Ethiopia encompasses five zones; namely, Jimma, 
Illu Ababora, Kafa, Sheka and Bench-Maji.  
The following definitions of terms were used in 
this study. 
Tuberculosis case: (1) Smear positive result of 
acid-fast bacilli or (2) TB confirmed by culture or 
(3) clinical sign and symptoms compatible with 
TB infection criteria by WHO or (4) Chest 
radiography confirmation. 
Children on HAART: Those who took 
combination therapy of 3 antiretroviral drugs that 
included two non-nucleoside reverse transcriptase 
and one protease inhibitor. 
Censored: Children who were lost, died, or 
transferred out or did not develop the events until 
the last visit. 
Source and study population: All children 
younger than 15 years having a follow-up care in 
ART clinics in southwest Ethiopia were source 
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population. Study population were all randomly 
selected HIV positive under 15 years old children 
registered from September 2009 to August 2014 
in Southwest Ethiopia. 
Exposure: Treatment with highly active 
antiretroviral treatment (HAART) for at least 2 
months. 
Outcome: TB illness.  
 
Inclusion and exclusion criteria: All under 15 
years old children on HAART or pre-HAART 
follow-up who were registered from September 
2009 to August 2014 were included in the study. 
However, all under 15 years old children who 
started anti-TB treatment at the beginning of 
follow-up and/or diagnosed as TB patients were 
excluded.   
Sample size and sampling procedure: Total, 844 
samples were determined using epi infoTM Version 
7. We took case-to-control ratio of 1:1. 
Fresh list of pediatrics ART Clinic in each 
zone were prepared. Then with proportional 
allocation methods, samples were selected from 
each ART clinic via systematic random sampling 
technique for both ART and pre-ART cohort.  
 
Data collection tool and procedure: A 
standardized tool which was adapted from existing 
literature was used. Adapted tools were translated 
into local languages by language experts. Then, 
relevant data was collected from patients’ pre-
ART and ART follow-up log books, database and 
other clinical records. To assure quality of data 
extraction, a pretest was conducted on 5% of the 
sampled population.  
 
Data entry and analysis: The collected data were 
coded, and double entry was made in EpiData 
version 3.1 statistical package. The analysis was 
made by Statistical Package for the Social 
Sciences (SPSS) version 23 software. Before 
analysis, the data were processed and cleaned by 
running frequency, sorting and cross-tabulation.  
Descriptive statistical techniques were carried out 
to describe the characteristics of the study 
subjects. 
We compared proportion of TB between non-
HAART and HAART cohorts by chi-square test. 
Besides, we compared median time of TB 
incidence between non-HAART and HAART 
cohorts using the Mann-Whitney test because the 
populations were independent and not normally 
distributed.  The incidence rate was calculated 
with Open Epi software and were expressed per 
100 child-years of follow-up on HAART. The TB 
free survival probability were constructed by the 
Kaplan-Meier method and compared between 
non-HAART and HAART groups by the log-rank 
test. The comparison was two- tailed with p-
values < 0.05.  
We estimated the effect of HAART on TB 
incidence by adjusting for confounders measured 
at baseline and time-varying intermediates. We 
did this by fitting weighted pooled logistic 
regression model to construct stabilized inverse 
probability of treatment and censoring (IPTC) 
weights. Then, these IPTC weights were used in a 
weighted pooled logistic regression model to 
approximate the parameters of a marginal 
structural Cox model (26). Confounders were 
selected based on previous studies. The covariates 
included in these models were age, sex, baseline 
clinical stage and baseline CD4 as baseline 
covariates. The time varying covariates were CD4, 
Clinical stage, follow-up status, adherence and 
CPT. 
Bivariable and multivariable Cox 
proportional hazard regression models were used 
to see independent predictors of TB incidence. 
Variables with p-value <0.2 in bivariable analysis 
were transferred to Multivariable cox proportional 
hazard model. In Multivariable analysis, variables 
with P-value <0.05 at 95% confidence level were 
considered as statistically significant predictors of 
TB incidence. The results were expressed as 
hazard ratios (HRs) with 95% confidence intervals 
(CI). 
RESULTS  
Of the total sample (844), 94.8% children were 
retrospectively followed. Half of them (50%) were 
non-HAART while 50% were HAART initiated. 
The median follow-up period for non- HAART 
was 47 months with IQR of 31 months whereas 
HAART initiated were followed for a median of 
53 months with IQR of 32 months. The total 
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follow-up period for non- HAART children and 
HAART initiated were 1469.08 and 1473.91 child 
years time respectively. The median and inter 
quintile range (IQR) of age for HAART cohort 
were 9 and 6 years respectively. The 
corresponding values for the pre-ART cohort were 
7 and 5 years respectively. Regarding gender, 
males constitute the largest proportion in both 
HAART (51%) and non-HAART (56.8%) groups.  
During a total of 2942.99 child-years follow-
up, 506 OIs occurred in 248 children (31%). The 
most common reported OIs were pneumonia 
(22%) and TB (29.1 %). Nearly 2% children died, 
7.8% transferred out, and 12.3% were lost to 
follow-up. Of 12.3% lost to follow-up, 35.7% 
were females, and the rest 64.3% were males. 
Sixty-five percent of the study subjects were 
either in WHO clinical stage I or II, while 65.3% 
had CD4 count above the threshold at enrollment.  
Baseline characteristics, children on HAART 
compared to those non-HAART later had a degree 
of advanced WHO clinical stage (p< 0.001).  
Children who had a baseline CD4 count below 
threshold had a more advanced HIV clinical stage 
(p=0.03), and they were more likely to have 
Tuberculosis (p<0.01). Children who initiated 
HAART had no difference compared to those who 
did not regarding gender (p=0.10). However, there 
was a difference regarding the medians of age 
across categories of the HAART cohort (p<0.001). 
The characteristics of study subjects are indicated 
in Table 1. 
 
Table 1: Characteristics of HAART initiated and HAART naïve children 
  
Time period  Characteristics  Category  HAART naïve HAART initiated 
 
   TB(No) TB (yes) TB(No) TB (yes) 
Baseline  Age  <1 3(27.3%) 8(72.7%) 0(0%) 18(100%) 
  1-3 56(59.6%) 38(40.4%) 21(48.8%) 22(51.2%) 
  3-5 45(81.8%) 10(18.2%) 41(67.2%) 20(32.8%) 
  5-15 176(73.3%) 64(26.7%) 225(80.9%) 53(19.1%) 
 Sex Male  148(65.2%) 79(34.8%) 127(62.3% 77(37.7%) 
  Female  132(76.3%) 41(23.7%) 160(81.6%) 36(18.4%) 
 WHO clinical stage  I 158(75.2%) 52(24.8%) 152(78.8%) 41(21.2%) 
  II 106(74.1%) 37(25.9%) 95(70.9%) 39(29.1%) 
  III 16(34.0%) 31(66.0%) 34(57.6%) 25(42.4%) 
  Iv 0(0%) 0(0%) 6(42.9%) 8(57.1%) 
 CD4  Below threshold 73(62.9%) 43(37.1%) 103(65.2%) 55(34.8%) 
  Above threshold 207(72.9%) 77(27.1%) 184(76.0%) 58(24.0%) 
 
*WHO-world health organization, †TB-Tuberculosis 
 
During the 2942.99 child-years of follow-up, 189 
children developed TB. The overall TB incidence 
rate was 7.917 per 100 child years (95% CI, 
6.933-9.002, whereas among HAART 7.667 per 
100 child-years (95% CI, 6.318-9.217) and 8.1686 
per 100 child-years (95% CI 6.772-9.767) for 
HAART naïve. The medians of time to event 
observation for children who started HAART was 
statistically similar with the medians observed for 
untreated children (p=0.229). In comparison, the 
proportion of non-HAART children who 
developed TB (29.5%) were higher than the 17.8 
% of HAART-initiated. However, no significant 
statistical difference was observed in terms of TB 
incidence between children on HAART and non-
HAART (p=0.641). 
The risk of TB was higher among children 
whose CD4 cell count was below threshold (200 
cells/mm3) compared to those children having 
CD4 count above threshold (200 cells/mm3). The 
incidence of TB had a direct relationship with age- 
as the age increased the risk also increased 
(p<0.001).  
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An unadjusted model that did not account for 
any confounder estimated no protective effect of 
HAART on TB incidence, relative to HAART 
naïve (HR 1.019, 95% CI 0.788–1.318, P=0.885). 
The unweighted model that adjusted baseline 
confounder suggested (HR 0.933, 95% CI 0.98–
0.712-1.224, P=0.618). Similarly, when we fitted 
weighted model appropriately accounting for 
baseline confounder, the result did not suggest 
protective effect of HAART (HR, 0.903, 95% CI: 
0.657-1.240, P=0.529).  However, the model that 
accounted for both the baseline and time-varying 
confounders using marginal structural models 
showed that HAART reduces the risk of 
tuberculosis; the HR from IPTC-weighted model 
was (HR, 0.642, 95%CI, 0.442-0.931, P=0.020) 
Table 2.  
 
Table 2: Estimated effect of HAART on TB incidence among 800 HIV-infected children initiating HAART, 
southwest Ethiopia, 2010-2014. 
 
 
Model  HR 95% CI p-value  
Unweighted and unadjusted  1.019 0.788-1.318 0.885 
Unweighted but adjusted  0.933 0.712-1.224 0.618 
Baseline Weighted and stabilized 0.903 0.657-1.240 0.529 
Time-varying  Weighted and stabilized 0.683 0.490-0.952 0.024 
Total Weighted and stabilized 0.642 0.442-0.931 0.020 
DISCUSSION  
 
The finding of this study showed, HAART 
noticeably had a protective effect against 
Tuberculosis among HIV infected children. Using 
a marginal structural model, we estimated that 
HAART reduced the rate of TB incidence by 36% 
relative to non-HAART. Although our method of 
analysis was different, this finding was supported 
by a study that estimated TB incidence among 
children after HAART was initiated (27–29). Our 
finding was in line with the effect observed with 
similar methods of analysis among adults in 
Europe and the United States (30). The similarity 
of these findings offers evidence that HAART is 
effective against TB in HIV-infected children in 
Southwest Ethiopia.  
The effect of HAART estimated in our study 
was lower than the effect revealed by similar 
studies in high income countries (31,32).  This 
difference could be resulted from the fact that 
pediatric HIV programs in Southwest Ethiopia 
like sub-Saharan Africa, often face challenges that 
could adversely increase TB among HIV infected 
children, including limited diagnostic capacity, 
delayed healthcare seeking and poor retention in 
care and under-nutrition (33). These factors 
underline why a similar protective effect of 
HAART on TB in children could not be expected 
across different settings.  
The incidence of tuberculosis among children 
on HAART in this study was 7.7 per 100 child-
years and for non-HAART group was 8.2 per 100 
child-years. Mathematically, it seems low; 
however, there is no statistically significant 
difference between the two groups. This finding is 
different from studies that supported reduced 
incidence of tuberculosis among HAART initiated 
(14,34,35).  
On the other hand, this study revealed lower 
incidence of TB among children on HAART 
compared to studies conducted in different parts 
of Ethiopia (6,24,25). The reasons for lower 
incidence rate in this study could be related to 
difference in study setting and period. Besides, 
lower incidence rate of TB could be related to 
limited access to health services and poor 
screening practice. The lower incidence can also 
be attributed to incompleteness of data on some 
patients which resulted in under estimation of 
incidence. 
In this study, high TB incidence was 
observed among CD4+ count strata below 
threshold for age during follow-up period. The 
result depicted an opposite relationship between 
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duration on HAART and TB incidence. This 
finding is consistent with other studies, and this 
may be due to better TB-specific immune repair 
with time spent on HAART (36)(37). We 
demonstrated that the high TB incidence rates 
observed in this study may be due to high ongoing 
community level TB transmission. Poor 
knowledge of the community regarding TB and 
poor health care access may resulted in higher TB 
incidence.  Most importantly, this might be 
justified with our selection criteria.  We selected 
cases with all diagnostic criteria including clinical 
criteria. The criteria might be less specific but 
highly sensitive.  
Our study has some limitations. In our 
selection criteria we suspected that we imposed 
unintentional classification of prevalent 
tuberculosis as incident tuberculosis. Children 
who received no screening for tuberculosis in their 
enrolment were followed and if in the meantime 
TB was developed then it was considered as 
incident cases. Besides, HAART was not 
randomly assigned, and thus the possibility of 
residual confounding cannot be ruled out. We also 
acknowledge that using clinical TB diagnostic 
criterion was the limitation of our study.    
The effect of HAART on TB incidence 
among HIV infected children in this study is the 
first valid estimate, to our knowledge, of the 
extent to which therapy decreases TB incidence in 
a highly relevant population of HIV-infected 
children living in Southwest Ethiopia. We 
analyzed data using marginal structural modeling 
to establish causal inference of HAART on TB 
incidence, which would be mentioned as strength 
of the study. Tuberculosis incidence in the study 
area was relatively high enough to be a public 
health problem.  
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